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Abstract. In spite of the major advantages that the liquisolid technology offers,
particularly in tackling poor bioavailability of poorly water-soluble drugs (i.e., BCS Class II
drugs), there are a few critical drawbacks. The inability of a high liquid load factor, poor
ﬂowability, poor compactibility, and an inability to produce a high dose dosage form of a
reasonable size for swallowing are major hurdles, hampering this technology from being
commercially feasible. An attempt was therefore made to overcome these drawbacks whilst
maintaining the liquisolid inherent advantages. This resulted in the emerging next generation
of oral dosage forms called the liqui-pellet. All formulations were incorporated into capsules
as the ﬁnal product. Solubility studies of naproxen were conducted in different liquid
vehicles, namely polyethylene glycol 200, propylene glycol, Tween 80, Labraﬁl, Labrasol, and
Kolliphor EL. The scanning electron microscopy studies indicated that the liquid vehicle
tends to reduce the surface roughness of the pellet. X-ray powder diffraction (XRPD)
indicated no signiﬁcant differences in the crystalline structure or amorphous content between
the physical mixture and the liqui-pellet formulation. This was due to the presence of a high
concentration of amorphous Avicel in the formulation which overshadowed the crystalline
structure of naproxen in the physical mixtures. Flowability and dissolution tests conﬁrmed
that this next-generation oral dosage form has excellent ﬂowability, whilst maintaining the
typical liquisolid enhanced drug release performance in comparison to its physical mixture
counterpart. The liqui-pellet also had a high liquid load factor of 1, where ~ 29% of the total
mass was the liquid vehicle. This shows that a high liquid load factor can be achieved in a
liqui-pellet without compromising ﬂowability. Overall, the results showed that the poor
ﬂowability of a liquisolid formulation could be overcomed with the liqui-pellet, which is
believed to be a major advancement into the commercial feasibility of the liquisolid concept.
KEY WORDS: liqui-pellet; liquisolid; dissolution enhancement; powder ﬂow; naproxen; solid state
analysis.
INTRODUCTION
Liqui-pellet is an emerging novel oral dosage form, which
improves the bioavailability of poorly water-soluble drugs via
increasing drug release rate in the GIT. The poor drug
dissolution rate of water-insoluble drugs is, in fact, a major issue
confronting the pharmaceutical industry (1). It is worth pointing
out that around 60%of drugs in themarket are poorly soluble in
gastrointestinal ﬂuids, which is based on biopharmaceutical
classiﬁcation system (BCS), and around 40% of drugs in
development are identiﬁed as poorly water soluble (2,3).
Liqui-pellet stems from combining liquisolid concept
with pelletization technology. It is fundamentally different
from liquisolid technology in that it does not ﬁt under the
deﬁnition of liquisolid system; hence, it is called liqui-pellet
instead of liquisolid pellet. Liquisolid formulation is described
to be under liquisolid system, which refers to powdered form
of liquid medication formulated by transforming liquid
lipophilic drugs, or drug suspensions or solutions of water-
insoluble drugs in an appropriate non-volatile liquid vehicle
into dry looking nonadherent, free-ﬂowing, and readily
compressible powder admixtures by incorporating speciﬁc
carriers and coating materials (4). In this study, the liqui-
pellet cannot be described as a liquisolid system because it is
not necessarily in powder form and the admixture is not
necessarily free-ﬂowing, but rather a cohesive wet mass. The
formulation only becomes free-ﬂowing after becoming a
pellet. In addition, the purpose of entitling the new dosage
form as liqui-pellet is to emphasize the high liquid load factor
or high amount of liquid vehicle it is capable of containing.
This implies that a high amount of liquid medication can be
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incorporated into the formulation, which can result in either
reduction in dosage weight or increased of API in solubilized
state, or both. The new system is described as liqui-mass
system, which is summarized in Fig. 1. The liqui-mass system
is versatile and different modiﬁcations can be applied to it. In
this study, the key focus is producing liqui-pellet via liqui-
mass system. However, it should be noted that this novel
technology is still in its infancy; there is a high degree of
ﬂexibility for modiﬁcation regarding liqui-pellet and the liqui-
mass composition as shown in Fig. 1.
In order to have a good grasp of liqui-pellet, it is important
to understand liquisolid technology. Liquisolid technology’s
simplistic approach and cost-effectiveness are desirable when
considering manufacturing at a commercial scale (5). In fact, the
excipients used are conventional and commonly available in the
market (5). In addition to enhanced drug release, the formula-
tion can bemanipulated to achieve sustained drug release with a
near zero-order release kinetic (6,7). Despite the advantages, it
has yet to overcome drawbacks, which hampers it from
becoming a commercial product. This is mainly due to major
issues such as poor ﬂowability, poor compressibility, and the
inability to produce high dose drug without being too bulky and
heavy, which is not ideal for swallowing (1,5). The ﬂow property
of the liquisolid blend is of critical importance in terms of
manufacturing, particularly tablet or capsule form, as ﬂow
property determines uniform feed and reproducible ﬁlling (8).
In brief, the concept of liquisolid system is comprised of
an active pharmaceutical ingredient (API), which is solubi-
lized in a liquid vehicle, forming the liquid medication. This
liquid medication is then incorporated into a carrier which is
coated with nano-sized coating material to give the admixture
of API and excipients a dry, free-ﬂowing, and readily
compressible properties (1,9).
Although there are other various technologies
confronting the issue of poor drug dissolution rate of water-
insoluble drugs, they may require advanced techniques,
sophisticated machinery, and complicated technology or may
not be cost-effective (5). The other technologies include
conversion of crystalline drug into its amorphous state (10),
micronization (11–14), solid dispersion (15), co-grinding (16–
18), nanosuspension (19,20), self-emulsifying drug delivery
system (21,22), and inclusion of drug solution in soft gelatin
capsule (23). But in most cases, long-term stability is an issue.
For example, on storage, highly amorphous materials can be
converted to crystalline state which usually changes drug
release proﬁle (24,25).
Since the focus of this study involves combining concept
from liquisolid technology with pelletization technology,
speciﬁcally extrusion-spheronization technology, the under-
standing of optimal extrudate properties for spheronization
and parameters affecting the formation of pellets is prudent.
In order to carry out wet extrusion, the material must display
sufﬁcient plastic property and cohesiveness to allow shaping
and retention of the extrudate. The extrudate for pellet
production should be self-lubricating and eventually brittle
but not friable (26). Moisture in the powder mass is one of the
major factors necessary for providing plasticity for extrusion
and spheronization, which have been subjected to much
research (27–32). Water content is found to be one of the
most important parameters (31). Other factors that can affect
pellets’ properties are water/granulating liquid temperature,
extrusion speed, spheronization speed, and spheronization
duration (30).
The aim of the present study is to make liqui-pellet,
which has the inherent advantages from both liquisolid and
pelletization technologies. The extrusion-spheronization tech-
nique can improve ﬂow property, and the inherent advan-
tages from the liquisolid aspect can enhance the drug release
rate. The authors have termed this next-generation oral
dosage form as liqui-pellet. This is to distinguish itself from
the classical liquisolid compact, to emphasize the high liquid
load factor it is capable of, and most importantly, to make
clear that it is fundamentally different from liquisolid
formulation in that it does not correspond to liquisolid
system, but instead to liqui-mass system. The excellent
ﬂowability of liqui-pellet means there is more room to
increase liquid load factor or the amount of liquid vehicle.
The inherent advantages from pelletization technology in-
clude reduced risk of side effects due to dose dumping,
combining incompatible drugs or drugs with different release
proﬁles in the same dose unit (33), and having good ﬂow
property (34).
MATERIALS AND METHODS
Materials
Naproxen was obtained from Tokyo Chemical Industry
Co (Japan). Other excipients used to prepare the liqui-pellet
included microcrystalline cellulose (Avicel PH-101), (FMC
Corp., UK); colloidal silicon dioxide (Aerosil 300), (Evonik
Industries AG, Hanau, Germany); polyethylene glycol 200
(Fisher Scientiﬁc, Leicester, UK); propylene glycol (SAFC,
Spain); polysorbate 80 (Tween 80), (Acros, Netherlands);
linoleoyl macrogol-6 glycerides (Labraﬁl), (Gattefosse, Saint
Priest, France); caprylocaproyl macrogol-8 glycerides
(Labrasol), (Gattefosse, Saint Priest, France); and
macrogolglycerol ricinoleate 35 (Kolliphor EL), (BASF SE,
Ludwigshafen, Germany). All other reagents and solvent
were of analytical grades.
Solubility Studies
Saturated solubility studies were carried out using 6
different liquid vehicles, i.e., polyethylene glycol 200 (PEG
200), propylene glycol (PG), Tween 80, Labraﬁl, Labrasol,
and Kolliphor EL (the liquid vehicles were selected on the
basis of the published articles and their solubilizing effect on
the drug (35,36). The primary objective of using various
mentioned liquid vehicles was to determine which liquid
vehicle was the most suitable liquid vehicle for enhanced
released naproxen liqui-pellet formulation. Saturated solu-
tions were prepared by adding excess pure naproxen in a
small vial containing 10 ml of speciﬁed liquid vehicle. The
sample was then left in a bath shaker (OLS Aqua Pro, Grant
Instruments Ltd., UK) for 48 h under a constant temperature
of 37°C and shaking speed of 40 rpm. The supernatant was
then ﬁltered through a pre-heated ﬁlter (pore size 0.22 μm,
Millex GP, Merck Millipore Ltd., Ireland), and diluted with
phosphate buffer solution. This was then analyzed via a UV/
vis spectrophotometer (Biowave II, Biochrom Ltd., UK) at
wavelength 271 nm to determine the concentration of
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naproxen in each sample. Each test was carried out in
triplicates.
Preparation of Naproxen Liqui-Pellet
The liqui-pellets were prepared by mixing pure naproxen
in a chosen liquid vehicle (PEG 200, PG, Tween 80, Labraﬁl,
Labrasol, and Kolliphor EL) using pestle and mortar method.
All formulations contained Avicel PH-101 and Aerosil 300 as
carrier and coating materials respectively, with a weight ratio
of carrier to coating material of 20 (R-value). The liquid load
factor for all liqui-pellet formulations was 1. Liquid load
factor is the ratio of the weight of liquid medication over the
weight of carrier excipient in the formulation admixture.
Avicel PH-101 was mixed into the admixture to make sure the
wet liquid medication was absorbed by the carrier and not
leaving residual in the mortar when transferred into a mixer
(Caleva Multitab, Caleva Process Solutions Ltd., UK). The
sample was mixed for 10 min at a constant rate of 125 rpm
with deionized water added bit by bit to achieve a desirable
plasticity for extrusion (Caleva Multitab, Caleva Process
Solutions Ltd., UK). The preliminary studies indicated that
water content was a crucial factor to achieve extrudate with
optimal plasticity for quality spherical pellet after
spheronization (Caleva Multitab, Caleva Process Solutions
Ltd., UK), which was further supported by the data published
in the literature (31). Aerosil 300 was then added into the
admixture and further mixed for 10 min before the extrusion-
spheronization process. Spheronization was set at an almost
constant rotation at 4000 rpm (decrease to 3500 rpm if
agglomeration seemed likely or increase to 4500 rpm to
increase pellet sphericity); however, in each formulation,
spheronization time varied depending on the extrudate
plasticity property. Pellets were then placed in an oven under
a constant temperature of 50°C overnight to remove water
from pellets. Table I shows the details of each formulation
with different liquid vehicles. Please note physical mixture
pellet was prepared in the same manner as liqui-pellet except
liquid vehicle was absent.
Evaluation of Naproxen Liqui-Pellet
Assay of Drug Content
Assays were carried out in all naproxen liqui-pellet
samples in order to conﬁrm that all formulations contained
the expected amount of drug that meets USP requirement of
90–110%. Assays were carried out via crushing speciﬁed
amount of pellets and dissolving the sample in a speciﬁed
amount of phosphate buffer solution (pH 7.4) for spectro-
photometric analysis (Biowave II, Biochrom Ltd., UK) at a
wavelength of 271 nm where naproxen can be detected. The
same method was used to test pure naproxen powder.
Flowability Test on Liqui-Pellet
Techniques of measuring ﬂow property of the liqui-pellet
that were used were ﬂow rate in grams per second
(Flowability tester, Copley Scientiﬁc, UK), angle of repose
(Flowability tester, Copley Scientiﬁc, UK, and Digimatic
height gauge, Mitutoyo, Japan), and Carr’s compressibility
index using the SVM tapped density tester (D-63150, Erweka,
Germany). The ﬂow rate was measured by recording the
weight (g) and time (s) of pellets ﬂowing through a 10-mm
diameter oriﬁce. The shutter was applied before funnel
became empty of pellets. To determine the angle of repose,
the pellets were placed in a funnel with a 10-mm diameter
oriﬁce and let the pellets ﬂow onto a 100-mm diameter
circular test platform. The digimatic height gauge and
micrometer were used to measure the height and diameter
of the heap of the sample, so that the angle of repose could be
determined. Carr’s compressibility index (CI%) was calcu-
lated from the poured (Pb) and tapped (Pt) densities using CI
equation (Eq. 1). Tapped density was measured using the
tapped density tester, which was set for 100 taps. All
measurements were done in triplicates.
CI% ¼ Pt–Pbð Þ=Pt  100 ð1Þ
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Fig. 1. Diagram summarizing the novel liqui-mass system which is used to make liqui-pellet
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Friability Test on Liqui-Pellet
Since there is no ofﬁcial standard for friability test on
pellets, friability test was adapted using a similar method
used by Hu et al. (37). All formulations were tested. Pellets
(3 g) and glass beads (3 g) were placed in a Erweka
friabilator (D-63150, Erweka, Germany) under constant
rotation of 25 rpm for 4 min. Note that the friabilator was
sealed in order to prevent pellets leaving the container.
Weight of the pellets before and after the friability test was
recorded in order to calculate % weight loss.
Particle Size Analysis via Sieve Method
Sieves (Test sieve, Retsch, Germany) were used to
determine the size distributions of all formulations. Pellets
(5 g) were sieved under vibration via a mechanical shaker
(AS 200, Retsch, Germany) for 1 min with an amplitude
of 50, then a further 9 min with an amplitude of 40, using
2000, 1000, 850, 500, and 250 μm sieves. The pellets’ yield
was determined based on the pellet fraction between 250
and 2000 μm and shown as the % of total pellet weight.
Stereoscopic Analysis
Stereoscopic analysis was performed on all formulations
using an optical microscope (Nikon Labophot, Nikon, Japan),
which was attached to a camera (Panasonic camera
WVCL310, Panasonic, Japan). This allowed the mean Feret’s
diameter, roundness, and elongation ratio to be calculated
using the particle size analysis software V1999 (designed in-
house at King’s College London). Note that 100 pellets per
formulation were analyzed and the roundness and elongation
ratio was calculated using Eqs. 2 and 3 respectively (38).
Roundness ¼ perimeterð Þ2= 4 πAreað Þ ð2Þ
Elongation ratio ¼ Maximum Feret diameter=Minimum Feret diameter
ð3Þ
Scanning Electron Microscope Analysis
A scanning electron microscope (Jeol JMS 820, Freising,
Germany) was used to observe the morphology of the pellets
of each formulation. Each sample was placed in a double-
sided carbon tape and sputter-coated with gold using a
sputter coater (Edwards S-150 Sputter Coater, Edwards High
Vacuum Co. International, USA) before placing in the
scanning electron microscope (SEM) machine. The surface
structure was then observed and recorded at magniﬁcations
of × 80, × 200, and × 800, using the SEM which was operating
at 3 kV.
In vitro Drug Release Test
All dissolution tests were carried out using USP paddle
method (708-DS Dissolution Apparatus & Cary 60 UV-Vis,
Agilent Technologies, USA). The formulations in the form of
liqui-pellets in capsules were under constant conditions of
900 ml of dissolution medium, paddle agitation of 50 rpm, and
temperature of 37.3 ± 0.5°C. Dissolution medium was either
HCl buffer solution of pH 1.2 or phosphate buffer solution of
pH 7.4 to simulate gastric ﬂuid and intestinal ﬂuid respec-
tively without enzymes. Absorbance (at 271 nm) was taken at
time intervals of 5 min until 1 h then time intervals of 10 min
for another hour.
All formulations contained 25 mg of naproxen. The
reason for choosing 25 mg of naproxen was because of
naproxen poor solubility proﬁle at pH 1.2 due to its weak
acidic properties. Naproxen would need to be able to dissolve
completely at pH 1.2 in order for the dissolution test to be
reliable. According to studies by Mora and Martinez (39),
naproxen solubility at 35°C and pH 1.2 was 1.16 × 10−4 mol/L
or 27 mg/L, hence 25 mg used in test seemed reasonable. As
for pH 7.4, naproxen was extremely soluble with a solubility
of 1.455 × 10−2 mol/L or ~3347 mg/L. It should be noted that
pH 1.2 sink condition was not maintained and this pH was
only used for comparison of various formulations.
Differential Scanning Calorimetry Studies
Differential scanning calorimetry (DSC) (DCS 4000,
Perkin Elmer, USA) was performed on the excipients,
pure naproxen, and the chosen formulations with the
fastest dissolution rate in order to assess their thermal
behavior. Samples weighing between 3 and 6 mg were
sealed in aluminum pan and thermal behavior was
investigated at a scanning rate of 10°C/min, from 25to
200°C under nitrogen atmosphere.
Table I. Key Formulation Characteristics of the Investigate Liqui-Pellet in Capsule
Formulation Liquid
vehicle
Liquid vehicle
concentration (% w/w)
Mass of
carrier (mg)
Mass of coating
material (mg)
Liquid load
factor
Total weight of 25 mg
naproxen liqui-pellet (mg)
Physical mixture pellet 68.97 3.13 90.63
LP-1 PEG 200 29.27 62.50 3.12 1 128.13
LP-2 PG 29.27 62.50 3.12 1 128.13
LP-3 Tween 80 29.27 62.50 3.12 1 128.13
LP-4 Labraﬁl 29.27 62.50 3.12 1 128.13
LP-5 Labrasol 29.27 62.50 3.12 1 128.13
LP-6 Kolliphor EL 29.27 62.50 3.12 1 128.13
Note, all formulation contains 25 mg of naproxen and the carrier to coating material is at a ratio of 20:1
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X-ray Powder Diffraction Studies
X-ray powder diffraction (XRPD) was performed using
an X-ray diffractometer (D5000, Siemens, Germany) on
naproxen, excipients, and selected formulations to character-
ize the solid state of the materials used. Samples were
scanned over a range of 2θ at a voltage of 40 kV and current
of 30 mA, with a scanning angle ranged from 5o to 40o and a
scan rate of 0.2o/s.
There were 2 methods of analyzing the % relative
crystallinity, which were integrated peak method (Eq. 4) and
peak height method (Eq. 5) (40). For integrated peak
method, the area under the peak was measured via the
trapezoid method. In Eq. 4, As is the integrated peak value of
a sample and Ar is the integrated peak value of a reference,
which is usually the pure API. In Eq. 5, Hs is the peak height
value of a sample and Hr is peak height value of a reference,
which is usually the pure API.
%XRD relative crystallinity ¼ As=Arð Þ x 100 ð4Þ
%XRD relative crystallinity ¼ Hs=Hrð Þ x 100 ð5Þ
Statistical and Mathematical Analysis
Mean cumulative % drug release after 2 h from the
dissolution test were statistically analyzed by one-way analy-
sis of variance (ANOVA). Results were quoted as signiﬁcant
where p < 0.05.
Speciﬁc mathematical equations were used to analyze
and compare dissolution proﬁles, which includes difference
factor (f1, Eq. 6) and similarity factor (f2, Eq. 7) as described
by Moore and Flanner (41). Both methods have been
recommended by the US FDA (Food and drug administra-
tion) (42) and implemented by the FDA in various guidance
documents (43,44). In brief, f1 value between 0 and 15 and f2
value between 50 and 100 indicates equivalence of the two
dissolution proﬁles (45). Details of the equations can be
found in various literature (42,46–48). The n represents the
number of dissolution sample times and Rt and Tt represent
the mean % of drug dissolved at each time point (t).
f 1 ¼ ∑t¼1njRt−Ttj½ = ∑t¼1nRt½ f g•100 ð6Þ
f 2 ¼ 50•log 1þ 1=nð Þ∑t¼1n Rt−Ttð Þ2
h i−0:5
•100
 
ð7Þ
RESULTS AND DISCUSSION
Solubility Studies
As shown in Table II, naproxen is most soluble in
Kolliphor EL liquid vehicle and least soluble in Tween 80.
Despite this, the formulation containing Tween 80 (LP-3)
unexpectedly showed the fastest dissolution rate at pH 1.2
(this will be discussed later in the manuscript). It is generally
thought that formulation containing the liquid vehicle with
the highest solubility to the drug would exhibit the fastest
drug release rate. This is due to less drugs in crystalline form
and more drugs are in solubilized or in molecularly dispersed
state in the carrier, thus increasing surface area for dissolution
(9).
It is noteworthy to point out that apart from drug
solubility, other physicochemical characteristics of liquid
vehicles such as lipophilicity, viscosity, polarity, chemical
structure, and molecular mass may affect drug release
behavior (1). Hence, this may be the reason why the solubility
result does not strictly match the drug release result.
Nonetheless, the solubility of the drug in a liquid vehicle is
a major factor that could greatly inﬂuence the drug release
proﬁle.
Extrusion and Spheronization
It should be noted that in the preliminary work, the
moisture level or plastic property of extrudates greatly affects
the success of spheronization. Extrudate plastic property is
directly linked to the amount of water added, which is the
granulating liquid. The more water added the greater degree
of plasticity. When the extrudate’s plasticity reaches above a
critical point, it would usually be in a form of long threads
rather than short threads (usually 3–5 cm) as shown in Fig. 2a.
This extrudate’s degree of plasticity was above the critical
point, resulting in agglomeration during the spheronization as
shown in Fig. 3a. However, below the critical point, shorter
extrudates are formed that successfully spheronized into
pellets as shown in Fig. 2b, c and Fig. 3b, c. Thus, ﬁnding
the optimal water content in extrudate has been seen prudent
in making liqui-pellets. In addition, spheronization speed and
time should be taken into account as high speed and long
duration of spheronization could lead to agglomeration.
It can also be seen in Fig. 3 that the quality of the pellets
from formulation (b) can be similar or better than that of
pellets without liquid vehicle (c). This could be due to liquid
vehicle improving the rheological property of the extrudate to
form good spherical pellets.
Evaluation of Naproxen Liqui-Pellet
Liqui-Pellet Flow Property
The results obtained from the ﬂowability studies
(Table III) indicate that liqui-pellet is indeed a very promising
approach to overcome poor ﬂowability with high liquid load
factor, which is one of the biggest hurdles in current liquisolid
technology. According to the angle of repose results
(Table III), all formulations achieved excellent ﬂow property
apart from LP-3, which is in the borderline between excellent
to good ﬂow property. CI% results (Table III) show that all
formulations achieved excellent ﬂow property. Such results
have never been achieved in liquisolid formulation with high
liquid load factor before. Although there was an improve-
ment in the ﬂow of liqusolid powders by applying the
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granulation technique (49), the liquid load factor was much
lower than the liquid-pellet in the current study.
It is interesting to see that the liquid load factor (Lf) in
liqui-pellet formulations is as high as 1 (Table I), which is
considered very high in liquisolid formulations. In fact, 28%
of the total mass of the pellets is co-solvent and yet the ﬂow
property is excellent. To put this into perspective, a compar-
ison with various studies will be discussed. For example, in
studies by Tiong and Elkordy, the naproxen liquisolid
composition highest Lf was 0.9 with very poor ﬂow property
(Carr’s index of 31.58) (35). Even the formulation with Lf of
0.168 only had fair ﬂow property (Carr’s index of 20) (35). In
studies by Javadzadeh et al., it is claimed that with the use of
an additive, such as PEG 3500, the Lf can be increased (36).
They observed an increase of carbamazepine Lf from 0.25 to
0.6, which is considered high (36). It can be seen clearly that
liqui-pellet Lf is much higher than the formulations in the
mentioned studies, and yet there are more rooms for liqui-
pellet to be optimized such as incorporating polymeric
additive. In studies by Hentzschel et al., a commonly used
carrier (Avicel of speciﬁc grade) and coating material
(Aerosil of speciﬁc grade) were replaced with Neusilin, which
had a much larger speciﬁc surface area (SSA) than Avicel to
make tocopherol acetate liquisolid tablet (50). This large SSA
increased the Lf from 0.22 to 1.58 (factor of ~ 7); however, it
was still limited by its ﬂow property.
With such high Lf in liqui-pellet whilst still achieving
excellent ﬂow property, the implication for commercial use is
very appealing as currently there is no liquisolid formulation
in the market. Liquisolid technology in itself has great merits
in the advantages it offers, but its drawbacks of poor
ﬂowability and larger mass of excipients in dosage form for
Table II. Solubility of Naproxen in Various Liquid Vehicles at 37°C
(n = 3)
Non-volatile solvent Mean concentration
(mg/ml) ± SDa
Inference
PEG 200 7.88 ± 4.87 Slightly soluble
PG 5.13 ± 0.78 Slightly soluble
Tween 80 2.99 ± 1.01 Slightly soluble
Labraﬁl 10.73 ± 1.15 Sparingly soluble
Labrasol 5.14 ± 2.44 Slightly soluble
Kolliphor EL 15.83 ± 0.77 Sparingly soluble
For the composition of each formulation, refer to Table I
a SD, standard deviation
Fig. 2. Image (a) of extrudate of a formulation (naproxen, Tween 80, Avicel, and Aerosil)
containing high water content, exhibiting high plasticity. Image (b) of extrudate of a
formulation (naproxen, PG, Avicel, and Aerosil) containing lower water content,
exhibiting lower plasticity. Image (c) of extrudate of physical mixture formulation
(naproxen, Avicel, and Aerosil)
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high dose drug have made it difﬁcult to establish itself for
commercial use. In fact, with high Lf and excellent ﬂowability,
it would seem possible that liqui-pellet can achieve acceptable
weight for high dose drug since poor ﬂow property is the key
reason for bulky dosage form. Formulations with poor
ﬂowability due to liquid medication require more carrier
and coating excipients to improve its ﬂow property, thus
increasing overall dosage form weight. The improvement of
dosage form weight is currently undergoing studies by the
authors. It would be fundamentally reasonable to postulate
that liqui-pellet is highly commercially feasible without having
the inherent advantages of liquisolid formulation
compromised.
It is also worth mentioning that due to ﬂow property not
being a major drawback in liqui-pellet, this effectively reduces
the reliance on the current liquisolid mathematical model
Fig. 3. Image (a) of agglomerated product after spheronizing a formulation (naproxen, Tween
80, Avicel, and Aerosil) containing high water content and longer threads. Image (b) of good
quality pellets (spherical particles with less size variation) after spheronizing a formulation
(naproxen, PG, Avicel, and Aerosil) containing lower water content and shorter threads.
Image (c) of reasonable quality pellets (dumbbell shape would be considered less quality but
reasonable) of physical mixture formulation (naproxen, Avicel, and Aerosil)
Table III. Flow Rate (g/s), Angle of Repose and Carr’s Compressible Index (CI%) of All Liqui-Pellet Formulation (n = 3)
Formulationa Flow rate (g/s) ± SDb Angle of repose ± SDb CI% ± SDb Inference according
to angle of repose
Inference according
to CI%
Physical mixture pellet 8.02 ± 0.24 27.95 ± 0.14 9.08 ± 0.87 Excellent ﬂow Excellent ﬂow
LP-1 8.85 ± 0.16 25.89 ± 0.95 6.07 ± 1.71 Excellent ﬂow Excellent ﬂow
LP-2 8.88 ± 0.07 23.53 ± 0.19 8.93 ± 0.93 Excellent ﬂow Excellent ﬂow
LP-3 5.67 ± 0.28 30.26 ± 0.09 3.38 ± 0.71 Excellent-good ﬂow property Excellent ﬂow property
LP-4 6.64 ± 0.23 27.37 ± 0.21 4.16 ± 1.67 Excellent ﬂow Excellent ﬂow
LP-5 7.10 ± 0.16 27.52 ± 0.24 3.18 ± 1.58 Excellent ﬂow Excellent ﬂow
LP-6 7.12 ± 0.07 29.24 ± 0.57 3.42 ± 0.00 Excellent ﬂow Excellent ﬂow
a For the composition of each formulation, refer to Table I
b SD, standard deviation from the mean
Page 7 of 16 231AAPS PharmSciTech (2019) 20: 231
introduced by Spireas (4). Flowable liquid-retention potential
and compressible liquid-retention need less attention in liqui-
pellet. In other words, high Lf can be achieved whilst
maintaining excellent ﬂow property, and compressibility is
not a major factor for pellets in capsules. Other parameters
such as R-value and choices of excipients may not need to be
compromised by ﬂow property.
Despite results obtained in this study, liqui-pellet and
liqui-mass system are still in its infancy; there are still areas
for further optimization in order to realize liqui-pellet full
potential, which at present is undergoing studies by the
authors.
Determination of the Amount of API in Liqui-Pellet
Formulation
Assay via a spectrophotometer (Table IV) shows that
all formulations except LP-2 have a good amount of drug
nearing to 100%. What is unusual is that LP-2 shows ~
30% more naproxen than expected. Initially, it is thought
that this is due to experimental or processing error and so
the LP-2 is remade but the assay still shows ~ 130% drug
content. The absorbance of 25 mg naproxen in 900 mL of
dissolution medium was increased from 0.47 ± 0.01 to 0.63
± 0.02 when this dissolution medium contained an addi-
tional 40 mg PG (this was exactly how much PG
associated with liqui-pellet formulation). The increase in
the absorbance value in the presence of PG was calcu-
lated to be around 34%. This is in agreement with the
dissolution data for LP-2 where the maximum dissolution
percentage for LP-2 was around 130% which is 30%
higher than expected. This indicates that the presence of
PG interferes with the wavelength used to measure
naproxen and this is the main reason for having more
than 100% drug release (130%) for the samples contain-
ing PG. There have been other cases when PG interfers
with absorbance reading such as in Dastidar and Sa
studies (51), where PG can interfere with the absorbance
of diazepam causing an increase in the absorbance
reading. It should be pointed out that since PG is not
the chosen suitable liquid vehicle for naproxen liqui-pellet,
there is no major issue concerning the interaction between
naproxen and PG.
Friability Test
The results obtained from the friability test (Table V)
show all formulations having % weight loss below 1%, which
is considered acceptable for tablets under USP standard. This
indicates that liqui-pellets are ideal for commercial
manufacturing as it is robust to friability. The microcrystalline
cellulose carrier forms strong bonding within its structure
when water is added, producing pellets with a strong structure
which is resistant to being friable. Also, the liquid vehicle in
liqui-pellet increases the pellet plasticity, which effectively
increases the pellet resistant to friability.
Particle Size of Liqui-Pellet via Sieve Method
In Fig. 4, it is clear that all formulations are mostly below
2 mm in size. Formulations LP-1, LP-3, LP-4, and LP-6 are
mostly within 1 mm. This shows that it is possible to produce
uniform size of liqui-pellet, which is important in regard to
quality control in manufacturing for commercial use.
Formulations LP-2 and LP-5 have a broader size
distribution with smaller size pellets compared to the rest of
the liqui-pellet formulations. In regard to formulation LP-2, ~
45% and ~ 35% of total pellet fall within 850 μm and 500 μm
respectively. As for formulation LP-5, ~ 51% and ~ 5.8% of
total pellet fall within 850 μm and 500 μm respectively. This
indicates the liquid vehicle can have an effect on liqui-pellet
size distribution, which can be assumed to be due to its effect
on extrudate plasticity. As for physical mixture pellet, which
does not contain liquid vehicle, ~ 77% of total pellet are
within 500 μm. Hence, it seems to indicate liquid vehicle
tends to increase pellet size.
Since all of the pellets are almost entirely equal or less
than 2 mm, it will be emptied from the stomach into the small
intestine relatively fast, similar to how liquid is emptied (52).
This is advantageous for weakly acidic drugs (i.e., naproxen),
as they undergo dissolution at a faster rate in less acidic and
more alkaline environment such as the small intestine. Hence,
it is suggested that the bioavailability and speed of drug
absorption may improve.
Stereoscopic Analysis
The Feret’s diameter, roundness, and elongation ratio
were calculated and shown in Table VI. In general, the
Feret’s diameter of the pellet seems to agree with most of the
results from particle size analysis. Thus, supporting the claim
Table IV. Spectrophotometric Assay (Wavelength 271 nm) Showing
% Drug Content in 25 mg Naproxen Formulations and Pure
Naproxen Powder (n = 3)
Formulationa Mean % drug release ± SDb
Pure naproxen powder 98.78 ± 0.23
Physical mixture pellet 96.54 ± 2.30
LP-1 95.68 ± 1.22
LP-2 129.68 ± 0.58
LP-3 100.88 ± 1.10
LP-4 101.84 ± 0.66
LP-5 99.94 ± 0.46
LP-6 101.79 ± 1.27
a For the composition of each formulation, refer to Table I
b SD, standard deviation from the mean
Table V. Weight Loss of 3 g of Each Formulation Under Rotational
Speed of 25 rpm for 4 min
Formulation % weight loss
Physical mixture pellet 0.54
LP-1 0.03
LP-2 0.00
LP-3 0.29
LP-4 0.53
LP-5 0.30
LP-6 0.43
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Fig. 4. Graph showing particle size distribution (PSD) of all formulations via sieve method
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that different liquid vehicles can inﬂuence pellet size and
generally increases the pellet size. However, there are some
discrepancies between the stereoscopic and particle size
analysis. It can be seen that the mean Ferret diameter of
the physical mixture pellet, LP-2, and LP-5 could be
overestimated. In fact, since the pellets are not perfectly
spherical and are usually in the most stable orientation,
meaning that the smallest dimension is orientated vertically;
therefore, overestimation is likely to occur (53). In reality, it is
actually difﬁcult to attain perfectly spherical particles.
Formulations LP-6, LP-5, and physical mixture pellet
showed the least roundness and largest elongation ratio.
Among them, LP-6 has the highest deviation from perfect
roundness (1.38) and largest mean elongation ratio (1.47).
Nevertheless, the pellets are good enough to achieve
excellent ﬂowability (Table III). As for the rest of the
formulations, the results seem to suggest the rest of the
liqui-pellets have good roundness and minimal elongation.
Morphological Studies on Pellets via SEM
According to Fig. 5, it can be seen that physical mixture
pellet (PMP) has a rougher surface structure than most of the
formulations. This seems to suggest that the co-solvent in
Table VI. Stereoscopic Analysis Showing the Mean Feret’s Diameter, Mean Roundness, and Mean Elongation of Each Formulation (n = 100)
Formulationsa Mean Feret’s diameter (mm) Mean roundness ± SDb Mean elongation ratio ± SDb
Physical mixture pellet 1.028 1.25 ± 0.12 1.41 ± 0.19
LP-1 1.294 1.12 ± 0.07 1.15 ± 0.10
LP-2 1.000 1.12 ± 0.03 1.17 ± 0.09
LP-3 1.517 1.14 ± 0.09 1.18 ± 0.17
LP-4 1.303 1.18 ± 0.07 1.25 ± 0.11
LP-5 1.268 1.24 ± 0.11 1.41 ± 0.21
LP-6 1.535 1.38 ± 0.18 1.47 ± 0.18
a For the composition of each formulation, refer to Table I
b SD, standard deviation from the mean
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Fig. 5. Images from SEM of all formulation; I. × 80 magniﬁcation, II. × 200 magniﬁcation, and III. × 800 magniﬁcation. Note
a refers to pellet before undergoing dissolution test and b SD refers to after dissolution test
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liqui-pellet formulations has an inﬂuence on the pellet surface
morphology, which generally results in a smoother surface. It
can be speculated that the dissolved crystals of naproxen in its
respective liquid vehicle have contributed to reducing the
overall crystallinity of the pellet. Given that all formulations
resisted disintegration after the dissolution test, surface
morphology after dissolution test was observed. The physical
mixture pellet surface structure is not much different from
before the dissolution test. As for most of the formulation
containing different types of co-solvent, it is observed that
their surface structure became rougher after undergoing
dissolution test. Since around 49% of the formulated liqui-
pellet is liquid medication, it is reasonable to suspect the
increase in roughness could be due to liquid medication
moving out from the pellet into the dissolution medium,
resulting the pellet reverting back to a more crystalline
structure or shrinking into a rougher surface structure. Also,
there may have been slight disintegration around the surface
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Fig. 6. Dissolution proﬁle of pellets in capsule for naproxen 25 mg with various liquid
vehicles and physical mixture pellet (pH 1.2)
0
10
20
30
40
50
60
70
80
90
0 20 40 60 80 100 120
esaeler
gurd
evitalu
mluc
%
nae
M
Time (minutes)
LP-1
LP-2
LP-3
LP-4
LP-5
LP-6
Physical mixture pellet
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Fig. 8. DSC traces of Avicel, Aerosil, physical mixture pellet, LP-3, LP-5, and LP-6. Note, the scales of excipients and
formulations are different in order to show the peak more clearly
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when the liquid medication leaves the pellet. The fact that it is
possible to study the morphology of the pellets after
undergoing dissolution test demonstrates the strong bonding
within the microcrystalline cellulose structure, rendering the
pellet non-disintegrating.
When observing liqui-pellet surface structure before
the dissolution test (Fig. 5), it can be observed that different
liquid vehicles give a different surface structure. Formula-
tions containing PEG 200 (LP-1) or Tween 80 (LP-3) have
similar surface structure and both produce relatively rough
surface in comparison to the other liqui-pellet formulations
(Fig. 5). Such surface structure is different from the
formulation containing PG (LP-2) or Kolliphor EL (LP-6)
where both produce smooth surface liqui-pellet. Liqui-pellet
containing Labraﬁl (LP-4) and Labrasol (LP-5) has a similar
surface structure to one another. As shown in Fig. 5, both of
their surface structure are relatively smooth but interest-
ingly have a smooth round bump that resembles micron-size
pebbles. It will be interesting to see how these various
surface morphologies may have an impact on the success of
applying coating techniques in these pellets in future
studies.
The results from the morphology studies and dissolu-
tion studies show no signiﬁcant correlation between surface
structures affecting the dissolution rate. This could be due
to the drug release rate being affected by many additional
factors as well as surface properties including drug solubility
and physicochemical characteristics of liquid vehicle (1).
Hence, this may be the reason why it does not appear to be
clear how surface structure affects the drug release rate.
Further studies on the surface structure are needed on liqui-
pellet to determine its impact on drug release.
Drug Release Study
The dissolution proﬁles of all formulations at pH 1.2
are shown in Fig. 6. It should be noted that, although
naproxen is poorly soluble in acidic condition and the
dissolution test should be carried out at higher pH or with
sink condition, for comparison purpose, the dissolution of
liqui-pellets was initially carried out at pH 1.2. It can be
seen clearly in Figs. 6 and 7 that liquid vehicle causes
considerable enhancement of drug release rate compared
to physical mixture pellet (p < 0.05), which does not
contain a liquid vehicle. The difference factor (F1) and
similarity factor (F2) of the best formulation (LP-3) and
physical mixture at acidic condition are 73.16 and 53.53
respectively. As seen, the F1 value indicates a marked
difference in dissolution proﬁle. The p value and F1 value
indicate that there is a difference in dissolution proﬁle. The
enhanced drug release via API solubilized or held at
molecularly dispersed state is maintained even after
extrusion and spheronization. This demonstrates that the
enhanced drug release mechanism via liquisolid concept
can be combined with the pelletization technique men-
tioned earlier.
Despite the solubility test (Table II), the dissolution
results at pH 1.2 (Fig. 6) show formulation with Tween 80
(LP-3) achieving the fastest drug release rate in comparison
to the other formulations with different liquid vehicles. Tween
80 has the fastest drug release rate followed by Kolliphor EL
(LP-6) then Labrasol (LP-5). Admittedly, even though the
formulation with Tween 80 has the fastest dissolution rate, the
percentage cumulative drug release is about 17% after 2 h,
which is poor. Nonetheless, the poor dissolution rate is
Fig. 9. Diffractograms of naproxen, Avicel, Aerosil, physical mixture pellet, LP-3, LP-5, and LP-6
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expected as naproxen is poorly soluble under acidic pH (37)
and the microcrystalline-based pellets are not suitable for fast
release formulation due to resistance to disintegration (54).
It is obvious that drug release rate increases signiﬁ-
cantly at pH 7.4 (Fig. 7); however, what is interesting is
that the formulation containing Labrasol (LP-5) has the
fastest drug release rate of ~ 75% after 2 h instead of
Tween 80 (LP-3), which is ~ 66% after 2 h. This shows a
different trend compared to the results when the pH is 1.2.
Their F1 and F2 are 9.23 and 66.04 respectively, indicating
little difference in dissolution proﬁle. Also, at pH 7.4,
Tween 80 (LP-3) and Kolliphor EL (LP-6) dissolution
proﬁle are almost identical (F1 = 1.43 and F2 = 95.66).
Furthermore, around 90 min during the dissolution test,
Labraﬁl (LP-4) drug release proﬁle is similar to that of
Tween 80 and Kolliphor EL. Such changes in dissolution
proﬁle in comparison to the results obtained at pH 1.2
suggest that pH can affect different liquid vehicles’
inﬂuence on drug release rate, and the degree of this
effect depends on the choice of liquid vehicle. Thus, the
effect of pH on different liquid vehicles seems fundamental
for future studies, particularly in choosing the most
appropriate co-solvent for a speciﬁc region of the gastro-
intestinal tract which the drug was supposed to be released
most efﬁciently in. In this case, the authors believe that
Tween 80 is the most suitable liquid vehicle since the aim
is to have a fast onset of action and fast drug release rate.
Thus, it is prudent that the drug release rate is high in
acidic condition as the drug will be in the stomach before
entering the small intestine. It should be noted that
although the aim is to have a fast onset of action and fast
drug release, in reality, a drug like naproxen would have
enteric coat due to potential GI irritation and the main site
of absorption will be in the small intestine.
Despite Labrasol having the best drug release at pH
7.4, Tween 80 drug release rate is only ~ 10% lower than
Labrasol. Nonetheless, Labrasol and Kolliphor EL may
also be a suitable liquid vehicle for naproxen. In studies by
Tiong and Elkordy, liquisolid tablet containing Kolliphor
EL (formerly known as cremophor EL) and naproxen of
20% w/w gave the fastest release, conﬁrming that
Kolliphor EL may also be a suitable liquid vehicle for
naproxen (35).
DSC Studies
Thermogram obtained from the DSC includes
naproxen, Avicel, Aerosil, Primojel, physical mixture
pellets, LP-3, LP-5, and LP-6 (Fig. 8). There is a sharp
endothermic peak (Tm = 158.77°C and ΔH= 92.06 J/g) for
naproxen, indicating its crystalline state. Avicel (Tm =
72.67°C and ΔH= 94.82 J/g) and Primojel (Tm = 83.82°C
and ΔH = 167.36 J/g) show broad peaks which could be
due to water within Avicel and Primojel evaporating, as
they are hygroscopic materials. The evaporation of water is
also observed by Tiong and Elkordy (48). Aerosil had no
deﬁnitive peak.
In the physical mixture pellet trace (Fig. 8), the peak is at
a lower temperature than naproxen (Fig. 8). The peak shifts
from 158.77°C (Fig. 8) to 149.80°C (Fig. 9), which could be
due to the Avicel affecting the overall peak of naproxen in
the physical mixture pellets. Nevertheless, the crystalline state
of naproxen is still present.
However, in formulation LP-3 (Tm = 120°C and ΔH=
1.9060 J/g), LP-5 (Tm = 111.98°C and ΔH= 2.4048 J/g), and
LP-6 (Tm = 121.48°C and ΔH= 3.5034 J/g), the DSC traces
show the absence of naproxen peak and that Tm is lower than
physical mixture. This indicates that liqui-pellets have re-
duced crystallinity and possibly have become more amor-
phous; thus, the improvement in dissolution.
XRPD Studies
Naproxen has major peaks at 2θ values of 12.2, 16.2,
18.4, 19.6, 22.2, 23.2, 26.8, and 27.8o (Fig. 9). These peaks are
similar to the naproxen diffractogram in Maghsoodi studies
(55). However, the differences are in the presence of a sharp
peak at ~ 7o and the absence of peak at 26.8o compared to
Maghsoodi studies. Naproxen peaks are also similar to
naproxen diffractogram in Mello and Ricci-Junior studies
(56), but again, there are some differences too. This could be
due to a different scan rate settings. Nonetheless, the main
diagnostic peaks of naproxen are present.
The physical mixture and the chosen formulation (LP-3,
LP-5, and LP-6) diffractograms (Fig. 9) have no peaks other
than that of naproxen and Avicel, which indicates no interaction
between the excipients and the API. It is clear from Fig. 9 that
physical mixture and formulation LP-3, LP-5, and LP-6 have
reduced crystallinity compared to the pure naproxen, agreeing
with the result observed in the DSC test. The reduced
crystallinity partially could be due to the presence of Avicel in
the samples particularly in the case of physical mixtures as the
drug should be in crystalline state. In the case of liquid-pellet
formulation, it could also be due to molecularly dispersion of
naproxen. From Fig. 9, it is difﬁcult to say physical mixture is
more crystalline compared to liquid-pellet formulations. This is
unusual and unexpected as it was assumed that liqui-pellet
would be less crystalline than the physical mixture pellet due to
the liquid vehicle dissolving the crystallineAPI. It is thought that
perhaps the amorphous nature of some of the excipients may
have overlapped naproxen sharp peaks in the physical mixtures.
Also, other factors such as inconsistency in particle size and
amount of sample place for XRPD may have inﬂuenced the
diffraction peak.
CONCLUSION
The emerging next-generation oral dosage form, liqui-
pellet, has shown remarkable results in terms of overcom-
ing the major drawbacks in liquisolid technology. Liqui-
pellet is able to achieve high liquid load factor whilst
maintaining excellent ﬂow property, which has never been
achieved in liquisolid technology before. Excellent-good
ﬂow property was obtained from all liqui-pellet formula-
tions which had liquid load factor of 1. This is one of the
key factors for the observed improvement in enhanced
drug release. With major drawbacks of liquisolid technol-
ogy being overcome using liqui-pellet, the liqui-pellet is
anticipated as a highly commercially feasible product.
Furthermore, there is potential for further optimization as
parameters, such as R-value, and choices of excipients may
not need to be compromised by ﬂow property.
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